Dr. Xia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1441 Eastlake Ave
Los Angeles, CA 90089Phone+1 323-865-3105
Education & Training
- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2011 - 2014
- Albert Einstein College of MedicineClass of 2011
- University of PennsylvaniaBA, Biology, Magna Cum Laude
Certifications & Licensure
- CA State Medical License 2017 - 2025
- CT State Medical License 2014 - 2020
- RI State Medical License 2017 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsRandomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.Aaron S Mansfield, Jun Vivien Yin, Penelope Bradbury, David J Kwiatkowski, Shiven Patel
Lung Cancer. 2024-09-01 - An improved 3D-UNet-based brain hippocampus segmentation model based on MR images.Qian Yang, Chengfeng Wang, Kaicheng Pan, Bing Xia, Ruifei Xie
BMC Medical Imaging. 2024-07-05 - 3 citationsReal world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer.Madeline MacDonald, Darin Poei, Alexis Leyba, Raymond Diep, Krithika Chennapan
Cancer Treatment and Research Communications. 2023-01-01
Abstracts/Posters
- HER2 Amplification in EGFR Mutant NSCLC After Acquired Resistance to EGFR-directed TherapiesBing Xia, Anna Wurtz, Scott N. Gettinger, Roy S. Herbst, Anne C. Chiang, Mimi Wan, Jeffrey Sklar, Veronique Neumeister, Katerina A. Politi and Sarah B. Goldberg, ASCO Annual Meeting, Chicago, IL, 6/4/2016
- HER2 Amplification in EGFR Mutant NSCLC After Acquired Resistance to First and Second Generation EGFR-InhibitorsBing Xia, Anna Wurtz, Scott N. Gettinger, Roy S. Herbst, Anne C. Chiang, Mimi Wan, Jeffrey Sklar, Veronique Neumeister, Katerina A. Politi and Sarah B. Goldberg, International Association for the Study of Lung Cancer (IASLC) 16th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA., 2/17/2016
- Effect of Primary Tumor Size in Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC)Bing Xia, Feng Gao, Ramaswamy Govindan, Damiel Morgensztern, ASCO Annual Meeting, Chicago, IL, 6/1/2013
- Join now to see all
Press Mentions
- OncLive® Hosts the Latest State of the Science Summit™ on Non-Small Cell Lung CancerApril 29th, 2019
Research History
- Oncology FellowResearch has focused on investigating biomarkers and novel treatment strategies in non-small cell lung cancer (NSCLC). Particular interest in evaluating mechanisms of resistance in EGFR mutant disease and therapies for brain metastasis.2014 - Present
Professional Memberships
- Member
- Member
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: